Immuno-oncology drugs have become the standard for cancer treatment as they can substantially improve side effects and survival rates compared to
conventional anticancer drugs. However, due to the low response rate of 20~30% in patients, the development of combination therapy drugs are
currently actively in progress to maximize the effect and increase the reaction rate of the immuno-cancer drugs.
TGF-β , which is over-expressed in tumor microenvironments, is reported as a major cause of low immuno-cancer drug reaction rate, and TGF-β is a fibrosis and immunosuppression factor that functions as follows. First, not only does it act as a strong immunosuppressive cytokine, second, it also promotes the formation and fibrosis of tumor microenvironment, third, it promotes the formation of new blood vessels in tumors, and the last, it contributes significantly to tumor metastasis.
By inhibiting various tumor promotion functions of TGF-β , our TGF-β inhibitor TU2218, first, has immune-cancer effects that inhibits immunodeficiency and immunosuppressive efforts of cancer cells and improves the tumor apoptosis in human immune cells, second, increase in tumor transfer rates of anti-cancer drugs that have been inhibited by fibrosis and hardening of tumor microenvironments, third, prevent tumor metastatic acquisition.
TU2218 is in its development phase as the anti-cancer drug based on the animal study showing the tumor inhibitory effect in a lone-administration as well as combination injections with PD-1/PD-L1 antibodies.